Business Context and Reporting Period
MiMedx Group, Inc. (MDXG) filed a Current Report on Form 8-K dated January 19, 2024, reporting the entry into a new material definitive credit agreement and the termination of its prior credit facility. The company is incorporated in Florida and trades on The Nasdaq Stock Market LLC.
Key Financial Metrics and Debt Structure
The filing details a new senior secured credit facility with an aggregate principal amount of up to $95.0 million, consisting of:
- Revolving Credit Facility: $75.0 million (includes a $10.0 million letter of credit sublimit and a $10.0 million swingline loan sublimit).
- Term Loan Facility: $20.0 million.
Initial Borrowings: On January 19, 2024, the company borrowed $30.0 million under the Revolving Credit Facility and $20.0 million under the Term Loan Facility.
Interest Rates: Borrowings bear interest at the Alternate Base Rate or Term SOFR plus an applicable margin. Margins range from 1.25% to 2.50% for Alternate Base Rate and 2.25% to 3.50% for Term SOFR, determined by the consolidated total net leverage ratio.
Maturity: All obligations are due in full on January 19, 2029.
Amortization: The Term Loan Facility amortizes quarterly at 1.25% (years 1-2), 1.875% (years 3-4), and 2.5% (year 5).
Financial Covenants: The agreement requires compliance with a maximum total net leverage ratio and a minimum consolidated fixed charge coverage ratio.
Material Changes Versus Prior Period
The company terminated its previous "Hayfin Credit Agreement" (originally dated June 30, 2020, and subsequently amended) immediately upon the closing of the new Credit Agreement. Proceeds from the new facility and cash on hand were used to repay in full all outstanding obligations under the Hayfin Credit Agreement. Consequently, the guarantees and liens associated with the prior agreement were released.
Outlook, Risks, and Unusual Items
Incremental Capacity: The company retains the option to increase commitments by the greater of $50.0 million or 1.00 times Consolidated EBITDA, subject to lender election.
Risks and Covenants: The agreement includes restrictive covenants limiting indebtedness, liens, fundamental changes, acquisitions, dividends, and other restricted payments. Events of default include failure to pay principal or interest, failure to provide notice of material events, or covenant breaches (subject to a 30-day grace period in certain circumstances).
Management Commentary: The filing references a press release issued on January 22, 2024, regarding the transaction but does not provide additional qualitative commentary within the text of the 8-K itself.
Investor Verification Checklist
- Verify the specific definitions of "Consolidated EBITDA," "Total Net Leverage Ratio," and "Fixed Charge Coverage Ratio" in the full Credit Agreement to assess covenant headroom.
- Confirm the exact interest rate margins applicable to the company's current leverage ratio.
- Review the full text of the Credit Agreement (to be filed in the Q1 2024 Form 10-Q) for detailed restrictive covenants regarding dividends and future acquisitions.
- Monitor the company's ability to meet the quarterly amortization schedule on the $20.0 million Term Loan.